Literature DB >> 28406674

Randomization to randomization probability: Estimating treatment effects under actual conditions of use.

Brandon J George1, Peng Li1, Harris R Lieberman2, Greg Pavela1, Andrew W Brown1, Kevin R Fontaine2, Madeline M Jeansonne1, Gareth R Dutton3, Adeniyi J Idigo1, Mariel A Parman2, Donald B Rubin4, David B Allison5.   

Abstract

Blinded randomized controlled trials (RCT) require participants to be uncertain if they are receiving a treatment or placebo. Although uncertainty is ideal for isolating the treatment effect from all other potential effects, it is poorly suited for estimating the treatment effect under actual conditions of intended use-when individuals are certain that they are receiving a treatment. We propose an experimental design, randomization to randomization probabilities (R2R), which significantly improves estimates of treatment effects under actual conditions of use by manipulating participant expectations about receiving treatment. In the R2R design, participants are first randomized to a value, π, denoting their probability of receiving treatment (vs. placebo). Subjects are then told their value of π and randomized to either treatment or placebo with probabilities π and 1-π, respectively. Analysis of the treatment effect includes statistical controls for π (necessary for causal inference) and typically a π-by-treatment interaction. Random assignment of subjects to π and disclosure of its value to subjects manipulates subject expectations about receiving the treatment without deception. This method offers a better treatment effect estimate under actual conditions of use than does a conventional RCT. Design properties, guidelines for power analyses, and limitations of the approach are discussed. We illustrate the design by implementing an RCT of caffeine effects on mood and vigilance and show that some of the actual effects of caffeine differ by the expectation that one is receiving the active drug. (PsycINFO Database Record (c) 2018 APA, all rights reserved).

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28406674      PMCID: PMC5640450          DOI: 10.1037/met0000138

Source DB:  PubMed          Journal:  Psychol Methods        ISSN: 1082-989X


  17 in total

Review 1.  Invited commentary: propensity scores.

Authors:  M M Joffe; P R Rosenbaum
Journal:  Am J Epidemiol       Date:  1999-08-15       Impact factor: 4.897

2.  Estimating causal effects from epidemiological data.

Authors:  Miguel A Hernán; James M Robins
Journal:  J Epidemiol Community Health       Date:  2006-07       Impact factor: 3.710

3.  Expectancy and pharmacology influence the subjective effects of nicotine in a balanced-placebo design.

Authors:  William L Kelemen; Farnaz Kaighobadi
Journal:  Exp Clin Psychopharmacol       Date:  2007-02       Impact factor: 3.157

4.  Fine as North Dakota wine: sensory expectations and the intake of companion foods.

Authors:  Brian Wansink; Collin R Payne; Jill North
Journal:  Physiol Behav       Date:  2007-01-03

5.  Relationship between probability of receiving placebo and probability of prematurely discontinuing treatment in double-blind, randomized clinical trials for MDD: a meta-analysis.

Authors:  Enrico Tedeschini; Maurizio Fava; Tracie M Goodness; George I Papakostas
Journal:  Eur Neuropsychopharmacol       Date:  2010-03-09       Impact factor: 4.600

Review 6.  Estimating causal effects from large data sets using propensity scores.

Authors:  D B Rubin
Journal:  Ann Intern Med       Date:  1997-10-15       Impact factor: 25.391

7.  Pre-existent expectancy effects in the relationship between caffeine and performance.

Authors:  Nicola A Elliman; Jennifer Ash; Michael W Green
Journal:  Appetite       Date:  2010-04-09       Impact factor: 3.868

8.  Health labelling can influence taste perception and use of table salt for reduced-sodium products.

Authors:  Djin Gie Liem; Fatemeh Miremadi; Elizabeth H Zandstra; Russell S J Keast
Journal:  Public Health Nutr       Date:  2012-03-08       Impact factor: 4.022

Review 9.  Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD.

Authors:  George I Papakostas; Maurizio Fava
Journal:  Eur Neuropsychopharmacol       Date:  2008-09-26       Impact factor: 4.600

10.  Balanced placebo design with marijuana: pharmacological and expectancy effects on impulsivity and risk taking.

Authors:  Jane Metrik; Christopher W Kahler; Brady Reynolds; John E McGeary; Peter M Monti; Margaret Haney; Harriet de Wit; Damaris J Rohsenow
Journal:  Psychopharmacology (Berl)       Date:  2012-05-16       Impact factor: 4.530

View more
  5 in total

1.  A randomized, placebo-controlled crossover trial of a decaffeinated energy drink shows no significant acute effect on mental energy.

Authors:  Alicia Garcia-Alvarez; Corbin A Cunningham; Byron Mui; Lia Penn; Erin M Spaulding; J Michael Oakes; Jasmin Divers; Stephanie L Dickinson; Xiao Xu; Lawrence J Cheskin
Journal:  Am J Clin Nutr       Date:  2020-03-01       Impact factor: 7.045

2.  Toward more rigorous and informative nutritional epidemiology: The rational space between dismissal and defense of the status quo.

Authors:  Andrew W Brown; Stella Aslibekyan; Dennis Bier; Rafael Ferreira da Silva; Adam Hoover; David M Klurfeld; Eric Loken; Evan Mayo-Wilson; Nir Menachemi; Greg Pavela; Dale Schoeller; Colby J Vorland; Leah D Whigham; David B Allison
Journal:  Crit Rev Food Sci Nutr       Date:  2021-10-22       Impact factor: 11.208

3.  Lessons from Randomised Clinical Trials for Triiodothyronine Treatment of Hypothyroidism: Have They Achieved Their Objectives?

Authors:  Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich
Journal:  J Thyroid Res       Date:  2018-07-16

4.  Time for a reassessment of the treatment of hypothyroidism.

Authors:  John E M Midgley; Anthony D Toft; Rolf Larisch; Johannes W Dietrich; Rudolf Hoermann
Journal:  BMC Endocr Disord       Date:  2019-04-18       Impact factor: 2.763

5.  Functional and Symptomatic Individuality in the Response to Levothyroxine Treatment.

Authors:  Rudolf Hoermann; John E M Midgley; Rolf Larisch; Johannes W Dietrich
Journal:  Front Endocrinol (Lausanne)       Date:  2019-09-26       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.